LEPU MED.T.B. SP.GDR O.N. Net Assets
LEPU MED.T.B. SP.GDR O.N. net assets. Based on the latest financial reports, LEPU MED.T.B. SP.GDR O.N. (07Z0) has net assets worth €17.98 Billion EUR (≈ $21.02 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€25.59 Billion ≈ $29.91 Billion USD) and total liabilities (€7.61 Billion ≈ $8.90 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of LEPU MED.T.B. SP.GDR O.N. to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.98 Billion |
| % of Total Assets | 70.25% |
| Annual Growth Rate | 9.68% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.93 |
Net Assets of LEPU MED.T.B. SP.GDR O.N. (2021–2025)
Net assets of LEPU MED.T.B. SP.GDR O.N. from 2021 to 2025. This chart illustrates how LEPU MED.T.B. SP.GDR O.N.'s net assets have evolved over time, based on quarterly financial data. Also explore LEPU MED.T.B. SP.GDR O.N. net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for LEPU MED.T.B. SP.GDR O.N. (2021–2025)
The table below shows the annual net assets of LEPU MED.T.B. SP.GDR O.N. from 2021 to 2025. For live market cap and overall valuation, see 07Z0 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €17.76 Billion ≈ $20.76 Billion |
+6.09% |
| 2024-12-31 | €16.74 Billion ≈ $19.57 Billion |
-4.33% |
| 2023-12-31 | €17.50 Billion ≈ $20.46 Billion |
+6.88% |
| 2022-12-31 | €16.37 Billion ≈ $19.14 Billion |
+33.39% |
| 2021-12-31 | €12.27 Billion ≈ $14.35 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LEPU MED.T.B. SP.GDR O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23.0% over the analyzed period, indicating profitable operations and earnings retention.
LEPU MED.T.B. SP.GDR O.N. Net Assets Breakdown (December 2025)
LEPU MED.T.B. SP.GDR O.N. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.99 Billion | 61.97% |
| Other Components | €6.13 Billion | 38.03% |
| Total Equity | €16.12 Billion | 100.00% |
LEPU MED.T.B. SP.GDR O.N. Competitors by Market Cap
The table below lists competitors of LEPU MED.T.B. SP.GDR O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sprott Physical Uranium Trust
TO:U-U
|
$175.07K |
|
Cambridge Cognition Holdings Plc
LSE:COG
|
$177.34K |
|
AVILA ENERGY CORP.
F:6HQ0
|
$177.76K |
|
Altitude Group Plc
LSE:ALT
|
$178.05K |
|
Kalium Lakes Ltd
AU:KLL
|
$174.54K |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
$174.17K |
|
ImagineAR Inc
F:GMS1
|
$173.97K |
|
HAVN LIFE SCIENCES INC.
F:5NP0
|
$172.31K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LEPU MED.T.B. SP.GDR O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,201,421,379 to 16,115,076,562, a change of 913,655,183 (6.0%).
- Net income of 962,006,333 contributed positively to equity growth.
- Dividend payments of 681,547,185 reduced retained earnings.
- Other factors increased equity by 633,196,035.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €962.01 Million | +5.97% |
| Dividends Paid | €681.55 Million | -4.23% |
| Other Changes | €633.20 Million | +3.93% |
| Total Change | €- | 6.01% |
Book Value vs Market Value Analysis
This analysis compares LEPU MED.T.B. SP.GDR O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.41x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.36 | €15.30 | x |
| 2022-12-31 | €8.05 | €15.30 | x |
| 2023-12-31 | €8.50 | €15.30 | x |
| 2024-12-31 | €8.08 | €15.30 | x |
| 2025-12-31 | €8.74 | €15.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LEPU MED.T.B. SP.GDR O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.97%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.84%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.62x
- Recent ROE (5.97%) is below the historical average (9.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 14.98% | 16.13% | 0.51x | 1.80x | €571.94 Million |
| 2022 | 14.55% | 20.77% | 0.43x | 1.62x | €689.06 Million |
| 2023 | 7.88% | 15.77% | 0.32x | 1.57x | €-339.41 Million |
| 2024 | 1.62% | 4.05% | 0.25x | 1.62x | €-1.27 Billion |
| 2025 | 5.97% | 14.84% | 0.25x | 1.62x | €-649.50 Million |
Industry Comparison
This section compares LEPU MED.T.B. SP.GDR O.N.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $58,018,045,917
- Average return on equity (ROE) among peers: -977.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | €17.98 Billion | 14.98% | 0.42x | $174.62K |
| BIORETEC OY (0TN) | $4.34 Million | -138.72% | 0.98x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $464.53 Billion | 11.55% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $76.93K | -8590.94% | 35.29x | $28.30 Million |
| Medtronic PLC (2M6) | $51.66 Billion | 7.27% | 0.76x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.27 Billion | -17.26% | 0.17x | $339.70 Million |
| AVITA Medical Inc (51KB) | $115.66 Million | -22.98% | 0.09x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.75 Billion | -16.50% | 0.09x | $107.57 Million |
About LEPU MED.T.B. SP.GDR O.N.
Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro d… Read more